Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cholecystectomy & appendectomy cases in Connecticut: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 29 | 1,576 | 46% |
| 2020 | 19 | 1,250 | 50% |
| 2021 | 27 |
The highest-volume laparoscopic cases; identifies every active general surgeon. Professional codes (what the surgeon bills): CPT 47562, 47563, 44970, 47600; the hospital bills MS-DRG 417, 418, 419, 338, 339, 340, 397, 398, 399.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 81% of the cases CMS names in Connecticut; 10 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 96 | 5,762−3.7%/yr | −3.7%/yr | 3.3 | 2% | 6,020 in 2030+0.7%/yr |
| Pennsylvania | 95 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 25 | 1,918−2.5%/yr | −2.5%/yr | 6.21.0× | 0% | 2,470 in 2030+4.3%/yr |
| Colorectal resection |
Cholecystectomy & appendectomy in every state, and its device makers · Every procedure market in Connecticut · Every state · Compare with New York
| ≈ 1,110 |
| – |
| 2026 est. | ≈ 1,160 | – |
| 1,392 |
| 53% |
| 2022 | 11 | 1,145 | 54% |
| 2023 | 11 | 1,129 | 57% |
| 2024 | 13 | 1,125 | 59% |
| 2025 from claims | – | 1,113 1,022–1,178 | 63% |
| 2026 forecast | – | 1,164 1,024–1,343 | 62% |
| 2027 forecast | – | 1,163 995–1,386 | 63% |
| 2028 forecast | – | 1,162 970–1,423 | 64% |
| 2029 forecast | – | 1,160 948–1,455 | 65% |
| 2030 forecast | – | 1,158 927–1,484 | 65% |
In 2025, 41% inpatient hospital, 59% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~1,200 | ~480 | ~680 |
| 2027 · ~1,200 | ~480 | ~680 |
| 2028 · ~1,200 | ~490 | ~680 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 58% (59% in 2025), inpatient hospital about 42% (41% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| 5,634−4%/yr |
| −4%/yr |
| 4.3 |
| 1% |
| 5,840 in 2030+0.6%/yr |
| New Jersey | 81 | 3,400−3.2%/yr | −3.2%/yr | 3.3 | 1% | 3,540 in 2030+0.7%/yr |
| Massachusetts | 60 | 3,162−3.7%/yr | −3.7%/yr | 3.4 | 0% | 3,520 in 2030+1.8%/yr |
| New Hampshire | 6 | 766−3%/yr | −3%/yr | 3.4 | 2% | 990 in 2030+4.4%/yr |
| Maine | 3 | 578−9.6%/yr | −9.6%/yr | 3.8 | 0% | 630 in 2030+1.4%/yr |
| Rhode Island | 4 | 359−3.4%/yr | −3.4%/yr | 4.1 | 0% | 360 in 2030−0.1%/yr |
| Vermont | 2 | 272−7%/yr | −7%/yr | 2.4 | 0% | 430 in 2030+8%/yr |
| 2 |
| 469−8.4%/yr |
| −8.4%/yr |
| 1.50.9× |
| 0% |
| 480 in 2030+0.5%/yr |
| Antireflux & hiatal hernia surgery | 4 | 214−7.4%/yr | −7.4%/yr | 0.61.1× | 0% | 200 in 2030−0.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
CONMED leads with 96% of company spending on these surgeons in 2025, +54 pts on 2024.
In 2025, 8 companies reported engagement with Connecticut’s surgeons worth $164K in consulting, speaking, meals and travel tied to these products, about $13K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 33 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.